[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-353926-105":59,"doc-detail-353926-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","inhibition-of-mapk-p38-overcomes-the-cancer-immunosurveillance-defect-caused-by-fpr1-loss-of-function-mutation","Inhibition of MAPK p38α overcomes the cancer immunosurveillance defect caused by FPR1 loss-of-function mutation","","An FPR1 loss-of-function polymorphism impairs dendritic cell migration, weakens cancer immunosurveillance, and accelerates early epithelial cancer development. A mouse model carrying a human-mimetic FPR1 mutation reproduces the dendritic cell defect seen in Fpr1 knockout animals. Genetic and pharmacological screening in cDC1 reveals that MAPK p38α inhibitors restore defective FPR1-dependent functions in vitro and in vivo, improving responses to anticancer chemotherapy and immune checkpoint blockade. Pharmacological p38α inhibition also normalizes accelerated colorectal carcinogenesis in immune-compromised models.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/inhibition-of-mapk-p38-overcomes-the-cancer-immunosurveillance-defect-caused-by-fpr1-loss-of-function-mutation/353926/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/inhibition-of-mapk-p38-overcomes-the-cancer-immunosurveillance-defect-caused-by-fpr1-loss-of-function-mutation/353926.png","ImageObject",300,407,{"name":92,"@type":93},"\tJames","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-31","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"How does FPR1 loss-of-function affect cancer development?","Question",{"text":112,"@type":113},"FPR1 loss-of-function compromises dendritic cell migration and weakens immunosurveillance, triggering precocious epithelial cancer manifestation.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What did the study identify as a way to correct the FPR1 defect?",{"text":117,"@type":113},"MAPK p38α inhibitors were found to correct the immune defect of FPR1-mutant dendritic cells in vitro and in vivo.",{"name":119,"@type":110,"acceptedAnswer":120},"What therapeutic effects were observed with MAPK p38α inhibition?",{"text":121,"@type":113},"Pharmacological p38α inhibition restored defective responses to anticancer chemotherapy and immune checkpoint blockade in mouse models, and normalized accelerated colorectal carcinogenesis.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},353926,1790280147,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},2336474466412,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","Article  \nInhibition of MAPK p38α overcomes the cancer immunosurveillance defect caused by FPR1 loss-offunction mutation  \nAuthors  \nYuhong Pan, Liwei Zhao, Jiani Liu, ..., Oliver Kepp, Peng Liu, Guido Kroemer  \nCorrespondence  \n[oliver.kepp@gustaveroussy.fr](oliver.kepp@gustaveroussy.fr) (O.K.),  \n[peng.liu@inserm.fr](peng.liu@inserm.fr) (P.L.),  \n[kroemer@orange.fr](kroemer@orange.fr) (G.K.)  \nIn brief  \nAn FPR1 mutation accelerates cancer onset by crippling dendritic cells and immunosurveillance. Pan et al. demonstrate that MAPK p38α inhibitors reverse this defect, restoring anti-tumor immunity and therapy responses in mice. This suggests a preventive strategy for individuals with this high-frequency immune polymorphism.  \n• MAPK p38α inhibition corrects the immune defect of FPR1-mutant dendritic cells  \n• Targeting p38α boosts chemo-and immunotherapy efficacy in FPR1-mutant settings  \n• Pharmacological p38α inhibition normalizes accelerated colorectal carcinogenesis  \nPan et al., 2026, Cell Reports Medicine 7, 102683  \nMarch 17, 2026 © 2026 The Author(s) . Published by Elsevier Inc.  \n[https://doi.org/10.1016/j.xcrm.2026.102683](https://doi.org/10.1016/j.xcrm.2026.102683)  \nll  \nll  \nOPEN ACCESS  \nArticle  \nInhibition of MAPK p38α overcomes the cancer immunosurveillance defect caused by FPR1 loss-of-function mutation  \nYuhong Pan,1,2,3,4,5,14 Liwei Zhao,1,2,14 Jiani Liu,1,2 Misha Mao,1,2,3 Ai-Ling Tian,1,2 Julie Le Naour,1,2  \nSarah Adriana Scuderi,1,2,6 Hui Pan,1,2,3 Flora Doffe,1,2 Donal Naylor,1,2,3 Hannah Felchle,1,2,7 Marie Valet,1,2,3 Maria Chiara Maiuri,1,2,8 Renyong Jia,4,5 Yuting Ma,9,10 Laurence Zitvogel,11,12 Oliver Kepp,1,2,* Peng Liu,1,2,15,* and Guido Kroemer1,2,13,*  \n1Metabolomics and Cell Biology Platforms, UMS AMMICa, Gustave Roussy Institute, Villejuif, France  \n2Centre de Recherche des Cordeliers, Equipe Labellis´ee Par La Ligue Contre le Cancer, INSERM U1138, Universit´e Paris Cit´e , Sorbonne Universit´e , Paris, France  \n3Facult´e de M´edecine, Universit´e Paris-Saclay, Paris, France  \n4Institute of Veterinary Medicine and Immunology, Sichuan Agricultural University, Chengdu, China  \n5Key Laboratory of Animal Disease and Human Health of Sichuan Province, Chengdu, China  \n6Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, Messina, Italy  \n7Technical University of Munich (TUM), TUM School of Medicine and Health, Klinikum Rechts der Isar, Department of Radiation Oncology, Munich, Germany  \n8Department of Molecular Medicine and Medical Biotechnologies, University of Napoli Federico II, Napoli, Italy  \n9National Key Laboratory of Immunity and Inflammation, Suzhou Institute of Systems Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Suzhou, China  \n10Collaborative Innovation Center for Cancer Personalized Medicine & Gusu School, Nanjing Medical University, Nanjing, China  \n11INSERM U1015, Equipe Labellis´ee-Ligue Nationale Contre le Cancer, Gustave Roussy Cancer Campus, Universit´e Paris-Saclay, Villejuif, France  \n12Department of Biology, Center of Clinical Investigations in Biotherapies of Cancer (CICBT) BIOTHERIS, Villejuif, France  \n13Institut Du Cancer Paris CARPEM, Department of Biology, Hˆopital Europ´een Georges Pompidou, AP-HP, Paris, France  \n14These authors contributed equally  \n15Lead contact  \n*Correspondence: [oliver.kepp@gustaveroussy.fr](oliver.kepp@gustaveroussy.fr) (O. K.), [peng.liu@inserm.fr](peng.liu@inserm.fr) (P. L.), [kroemer@orange.fr](kroemer@orange.fr) (G. K.) [https://doi.org/10.1016/j.xcrm.2026.102683](https://doi.org/10.1016/j.xcrm.2026.102683)  \nSUMMARY  \nA loss-of-function polymorphism affecting the N-terminus of human formyl peptide receptor 1 (FPR1) leads toa single amino acid exchange that compromises dendritic cell (DC) migration, weakens immunosurveillance, and triggers the precocious manifestation of epithelial cancers. We present a mouse model bearing a humanmimetic mutation in FPR1 that ","cbCaigenWMJ7nbv5","https://ap.wps.com/l/cbCaigenWMJ7nbv5","pdf",34541057,29,"English","# Summary\n# Introduction\n# Summary of findings","[{\"question\":\"How does FPR1 loss-of-function affect cancer development?\",\"answer\":\"FPR1 loss-of-function compromises dendritic cell migration and weakens immunosurveillance, triggering precocious epithelial cancer manifestation.\"},{\"question\":\"What did the study identify as a way to correct the FPR1 defect?\",\"answer\":\"MAPK p38α inhibitors were found to correct the immune defect of FPR1-mutant dendritic cells in vitro and in vivo.\"},{\"question\":\"What therapeutic effects were observed with MAPK p38α inhibition?\",\"answer\":\"Pharmacological p38α inhibition restored defective responses to anticancer chemotherapy and immune checkpoint blockade in mouse models, and normalized accelerated colorectal carcinogenesis.\"}]","Inhibition of MAPK p38α overcomes the cancer immunosurveillance defect caused by FPR1 loss-of-function mutation | PDF",1790107970,73,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/14e2eae82c48f7a0bc14abd90313018a.webp",983,1276,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/feef6a13112ad666cee3acc0ad72b238.webp",982,1275,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c34daa14f9b88ab4f5a2f124270f837f.webp",981,1273,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8a27eecb1f58d0f6c8cea59b65a35280.webp",980,1272]